2024-03-28T19:31:56Z
https://u-ryukyu.repo.nii.ac.jp/oai
oai:u-ryukyu.repo.nii.ac.jp:02016892
2022-02-22T07:18:47Z
1642838163960:1642838198944:1642838199408:1642838231050
1642838403551:1642838412624
Evaluation of candidate therapies using a patient-derived cervical cancer xenograft model
Nagayama-Urasoe, Chiaki
Umikawa, Masato
Asato, Tsuyoshi
Nagai, Yutaka
Aoki, Yoichi
Kariya, Ken-ichi
open access
琉球医学会
cervical cancer
patient-derived xenograft
gemcitabine
cediranib
salinomycin
Patient-derived xenograft (PDX) models are useful for preclinical evaluation of anticancer agents. However, establishing PDX models of cervical cancers are known to be challenging. We modified a protocol from the existing literature and established a model of an HPV16-positive squamous cell carcinoma on scid mice. The xenograft was positive for p16INK4a even after a passage, indicating the continued involvement of the E7 viral oncoprotein in abnormal cell growth. After 24 days of treatment with a nucleoside analog, gemcitabine, tumor growth was found to be suppressed in a dose-dependent manner, and the tumor became undetectable after high-dose treatment. Cediranib, an orally bioavailable inhibitor of neovascularization, reversed tumor growth until it was barely detectable. A hydrophobic cancer stem cell inhibitor, salinomycin, did not show any significant effect when used alone, but showed a tendency to act synergistically with low-dose gemcitabine. Although further procedural refinements are required, the model appeared to be useful for preclinical evaluation of various anticancer agents, including novel ones that target specific molecules.
論文
琉球医学会
Ryukyu Medical Association
eng
journal article
VoR
http://hdl.handle.net/20.500.12000/0002016892
https://u-ryukyu.repo.nii.ac.jp/records/2016892
1346-888X
AN10369445
琉球医学会誌 = Ryukyu Medical Journal
36
1-2
25
28
https://u-ryukyu.repo.nii.ac.jp/record/2016892/files/v36(1-2)p25.pdf